Hemispherx Biopharma Board Names Thomas Equels as New President

Hemispherx Biopharma, Inc. (NYSE MKT: HEB) today announced that the Board has appointed Thomas Equels as the new President for Hemispherx Biopharma Inc. According to Peter Rodino, Chairman of the Audit Committee and an Independent Director, "On behalf of the Independent Directors, we are pleased to announce Equels' expanded role in providing a strong new executive emphasis creating greater operational efficiencies through seeking to achieve significant operational savings. He will also have a clear mandate from the Board to strengthen internal controls, achieve enhanced governance, and create an environment for greater stockholder value. This strengthened executive role, we believe, will far better serve our corporate goals." See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsManagementPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!